Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
DNA Total Current Assets
All assets expected to be converted to cash or used up within one year.
Ginkgo Bioworks Holdings, Inc.NYSE: DNA
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 27.4% from a year ago
Total current assets stood at $409.96M at the end of Q1 FY2026, down 27.4% from a year earlier and down 13.1% from the prior quarter. Over 3 fiscal years it compounded at -31.2% a year.
Context
- Total current assets amounted to 39.7% of total assets at the end of Q1 FY2026, down 4.0 pp from a year earlier.
- Total current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -27.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 471.84M USD
- Year-over-year change
- -21.7%
- 4-year CAGR
- -27.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 471.84M | -21.7% |
| FY2024 | 2024-12-31 | 602.74M | -39.8% |
| FY2023 | 2023-12-31 | 1B | -30.9% |
| FY2022 | 2022-12-31 | 1.45B | -15.8% |
| FY2021 | 2021-12-31 | 1.72B | — |
Total Current Assets vs competitors
How DNA compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -27.4% is the 5th highest of 10, against a peer median of -29.8%.
- Total current assets amounts to 39.7% of total assets for DNA, versus a peer median of 55.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $630.7M USD | -35.6% | -17.3% | 97.4% | |
| Sep 2026 | $549.64M USD | +28.1% | -2.6% | 55.5% | |
| Mar 2026 | $522.99M USD | -43.9% | -41.1% | 51.0% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $492.76M USD | +24.0% | +105.1% | 98.4% |
| Mar 2026 | $409.96M USD | -27.4% | -31.2% | 39.7% | |
| Mar 2026 | $348.7M USD | +87.7% | +22.2% | 99.8% | |
| Dec 2025 | $280.35M USD | -48.8% | +7.1% | 84.0% | |
| Mar 2026 | €201.65M EUR | -29.8% | -19.4% | 54.1% | |
| Jun 2026 | $155.66M USD | -56.7% | -29.6% | 25.8% | |
| Mar 2026 | $96.2M USD | +20.4% | -15.9% | 39.3% | |
| Peer median (excluding DNA) | — | -29.8% | -15.9% | 55.5% | |
Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.55B | 1.32B | 944.07M | 561.57M | 167.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 255.42M |
| Net Receivables | 149.9M | 84.03M | 17.9M | 22.44M | 24.03M |
| Inventory | 3.36M | 4.36M | 46K | 0 | 0 |
| Other Current Assets | 698K | 8.71M | 18.99M | 18.73M | 25.19M |
| Total Current Assets | 1.72B | 1.45B | 1B | 602.74M | 471.84M |
| Property, Plant & Equipment (Net) | 145.77M | 718.79M | 394.99M | 598.16M | 528.7M |
| Goodwill | 21.31M | 60.21M | 49.24M | 0 | 0 |
| Intangible Assets | 21.64M | 111.04M | 82.74M | 72.51M | 56.92M |
| Long-term Investments | 115.23M | 111.79M | 77.91M | 48.7M | 15.07M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 43.99M | 87.41M | 58.71M | 55.34M | 47.17M |
| Total Non-current Assets | 347.95M | 1.09B | 663.59M | 774.71M | 647.86M |
| Total Assets | 2.07B | 2.54B | 1.67B | 1.38B | 1.12B |
| Account Payables | 8.19M | 10.45M | 9.32M | 14.17M | 10.57M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 33.24M | 47.82M | 48.5M | 30.6M | 19.98M |
| Other Current Liabilities | 40.31M | 52.51M | 54.38M | 26.62M | 32.12M |
| Total Current Liabilities | 134.76M | 172.96M | 163.86M | 107.27M | 95.97M |
| Long-term Debt | 0 | 0 | 0 | 0 | 417.08M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 155.99M | 174.77M | 158.06M | 98.78M | 0 |
| Other Non-current Liabilities | 190.58M | 42.06M | 24.43M | 16.58M | 98.06M |
| Total Non-current Liabilities | 368.85M | 630.08M | 404.33M | 554.13M | 515.14M |
| Total Liabilities | 503.61M | 803.04M | 568.19M | 661.39M | 611.11M |
| Common Stock | 161K | 190K | 5K | 5K | 6K |
| Retained Earnings | (2.3B) | (4.4B) | (5.29B) | (5.84B) | (6.15B) |
| Accumulated OCI | (1.72M) | (2.63M) | 1.48M | (1.81M) | 1.85M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 62.01M | 0 | 0 | 0 | 0 |
| Total Equity | 1.57B | 1.74B | 1.1B | 716.06M | 508.59M |
| Total Debt | 23.03M | 442.59M | 239.31M | 467.73M | 439.89M |
| Net Debt | (1.53B) | (873.2M) | (704.76M) | (93.84M) | 272.68M |
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.